Sign in
SAVA Stock Price, Chart, Stats & News
Cassava Sciences, Inc.
Save
63.77M
Market cap
–
Current P/E
151.52x
Forward P/E
SAVA chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -76.86% |
ROE | -97.94% |
D/E | – |
Interest coverage ratio | – |
SAVA valuation
P/E | – |
P/S | – |
P/B | 1.27x |
P/CF | -2.93x |
P/FCF | -2.88x |
P/OCF | -2.93x |
PEG | -0.07x |
EV multiple | -2.01x |
About
Cassava Sciences, Inc. is a biopharmaceutical enterprise in the clinical development phase, specializing in the creation of treatments for neurodegenerative disorders. The company's primary experimental drug, simufilam, a small-molecule compound, has successfully concluded its Phase 2b clinical trials. In parallel, they are advancing SavaDx, an investigational blood-based biomarker test designed to aid in the detection of Alzheimer's disease.
Similar securities
Based on sector and market capitalization
Report issue